Carpenter Technology Ready to Report Q4 Earnings: What's in Store?
Image Source: Zacks Investment Research
CRS's Solid Earnings Surprise History
Carpenter Technology's earnings beat the Zacks Consensus Estimates in the trailing four quarters, the average surprise being 11.1%.
Image Source: Zacks Investment Research
What the Zacks Model Unveils for Carpenter Technology
Our proven model does not conclusively predict an earnings beat for CRS this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. But that is not the case here, as you can see below.You can uncover the best stocks before they are reported with our Earnings ESP Filter.Earnings ESP: Carpenter Technology has an Earnings ESP of -3.07%.Zacks Rank: CRS currently has a Zacks Rank of 2.
Factors Likely to Have Shaped CRS's Q4 Performance
Carpenter Technology has been witnessing growth across its end-use markets, especially in aerospace, defense and medical applications, which is anticipated to continue throughout fiscal 2025 and get reflected in the fourth-quarter fiscal 2025 results. In the quarter, demand is expected to have accelerated across all aerospace submarkets as the supply chain ramped up to meet increasing travel demand.However, the company has been bearing the brunt of labor and chip shortages, which are likely to have affected its performance.Nonetheless, gains from increased productivity across Carpenter Technology's facilities, higher prices, an improved product mix and increased volumes are expected to have negated these headwinds. The impacts of these are likely to get reflected in the company's margin results.We expect the Specialty Alloys Operations segment's sales to be $689 million in the quarter, indicating a dip of 3.7% from the year-ago quarter's reported figure. Our model estimates the segment to sell 47,322 pounds in the fourth quarter of fiscal 2025, indicating a dip of 17.3% from that reported in the fourth quarter of fiscal 2024. We expect the operating profit to be $163 million, indicating growth from the $141 million reported in fourth-quarter fiscal 2024.We expect Performance Engineered Products' net sales to rise 1.5% year over year to $113 million. Our model predicts the segment to sell 2,843 pounds in the quarter, indicating a decrease of 0.5%. Our estimate for the segment's operating profit is $11.7 million. The segment reported an operating profit of $10.6 million in the year-ago quarter.
Carpenter Technology Stock's Price Performance
CRS shares have skyrocketed 97.4% in the past year compared with the industry's 46.7% growth.
Image Source: Zacks Investment Research
Stocks to Consider
Here are some Basic Materials stocks, which, according to our model, have the right combination of elements to post an earnings beat in their upcoming releases.Pan American Silver Corp. PAAS, slated to release second-quarter 2025 earnings on Aug 6, has an Earnings ESP of +3.09% and flaunts a Zacks Rank of 1 at present. You can see the complete list of today's Zacks #1 Rank stocks here.The consensus mark for Pan American Silver's revenues is $766.8 million, indicating year-over-year growth of 11.7%. The Zacks Consensus Estimate for PAAS' earnings for the second quarter is pegged at 39 cents per share. The estimate indicates a significant climb from the earnings of 11 cents per share reported in the year-ago quarter. PAAS has a trailing four-quarter average earnings surprise of 36.7%.
Agnico Eagle Mines Limited AEM, scheduled to release second-quarter earnings on July 30, has an Earnings ESP of +7.97% and a Zacks Rank of 3. The Zacks Consensus Estimate for Agnico Eagle Mines' revenues is $2.55 billion, implying year-over-year growth of 22.9%. AEM's earnings for the second quarter are pegged at $1.69 per share, indicating a year-over-year jump of 57.9%. Agnico Eagle Mines has a trailing four-quarter average earnings surprise of 12.3%.CSW Industrials, Inc. CSW, slated to release first-quarter fiscal 2026 earnings on July 31, has an Earnings ESP of +4.38% and a Zacks Rank of 3 at present.The consensus mark for CSW Industrials' fiscal first-quarter revenues is $277 billion, implying year-over-year growth of 22.5%. The consensus mark for earnings is pegged at $2.74 per share. It indicates a year-over-year rise of 10.9%.CSW Group has a trailing four-quarter average earnings surprise of 7.8%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Carpenter Technology Corporation (CRS) : Free Stock Analysis Report
Agnico Eagle Mines Limited (AEM) : Free Stock Analysis Report
Pan American Silver Corp. (PAAS) : Free Stock Analysis Report
CSW Industrials, Inc. (CSW) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Analysts Estimate Haemonetics (HAE) to Report a Decline in Earnings: What to Look Out for
Haemonetics (HAE) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 7. On the other hand, if they miss, the stock may move lower. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise. Zacks Consensus Estimate This provider blood management systems for health care providers and blood collectors is expected to post quarterly earnings of $1.01 per share in its upcoming report, which represents a year-over-year change of -1%. Revenues are expected to be $303.28 million, down 9.8% from the year-ago quarter. Estimate Revisions Trend The consensus EPS estimate for the quarter has been revised 0.22% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. Price, Consensus and EPS Surprise Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). How Have the Numbers Shaped Up for Haemonetics? For Haemonetics, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +1.24%. On the other hand, the stock currently carries a Zacks Rank of #4. So, this combination makes it difficult to conclusively predict that Haemonetics will beat the consensus EPS estimate. Does Earnings Surprise History Hold Any Clue? While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that Haemonetics would post earnings of $1.22 per share when it actually produced earnings of $1.24, delivering a surprise of +1.64%. Over the last four quarters, the company has beaten consensus EPS estimates two times. Bottom Line An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Haemonetics doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. An Industry Player's Expected Results Evolus, Inc. (EOLS), another stock in the Zacks Medical - Products industry, is expected to report loss per share of $0.09 for the quarter ended June 2025. This estimate points to a year-over-year change of -28.6%. Revenues for the quarter are expected to be $82.93 million, up 23.9% from the year-ago quarter. The consensus EPS estimate for Evolus has remained unchanged over the last 30 days. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -28.57%. This Earnings ESP, combined with its Zacks Rank #3 (Hold), makes it difficult to conclusively predict that Evolus will beat the consensus EPS estimate. The company could not beat consensus EPS estimates in any of the last four quarters. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report Evolus, Inc. (EOLS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Haemonetics (HAE) Q1 Earnings and Revenues Surpass Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.1 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $1.02 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +8.91%. A quarter ago, it was expected that this provider blood management systems for health care providers and blood collectors would post earnings of $1.22 per share when it actually produced earnings of $1.24, delivering a surprise of +1.64%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Haemonetics, which belongs to the Zacks Medical - Products industry, posted revenues of $321.39 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.97%. This compares to year-ago revenues of $336.17 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Haemonetics shares have lost about 3% since the beginning of the year versus the S&P 500's gain of 7.9%. What's Next for Haemonetics? While Haemonetics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Haemonetics was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.16 on $321.11 million in revenues for the coming quarter and $4.89 on $1.3 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Phibro Animal Health (PAHC), another stock in the same industry, has yet to report results for the quarter ended June 2025. This maker of animal health products and nutritional supplements is expected to post quarterly earnings of $0.52 per share in its upcoming report, which represents a year-over-year change of +26.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Phibro Animal Health's revenues are expected to be $361.15 million, up 32.2% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Boston Scientific (BSX) Q2 Earnings and Revenues Surpass Estimates
Boston Scientific (BSX) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +4.17%. A quarter ago, it was expected that this medical device manufacturer would post earnings of $0.67 per share when it actually produced earnings of $0.75, delivering a surprise of +11.94%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Boston Scientific, which belongs to the Zacks Medical - Products industry, posted revenues of $5.06 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.48%. This compares to year-ago revenues of $4.12 billion. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Boston Scientific shares have added about 15.5% since the beginning of the year versus the S&P 500's gain of 7.3%. What's Next for Boston Scientific? While Boston Scientific has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Boston Scientific was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.70 on $4.85 billion in revenues for the coming quarter and $2.91 on $19.5 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 30% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Haemonetics (HAE), is yet to report results for the quarter ended June 2025. The results are expected to be released on August 7. This provider blood management systems for health care providers and blood collectors is expected to post quarterly earnings of $1.01 per share in its upcoming report, which represents a year-over-year change of -1%. The consensus EPS estimate for the quarter has been revised 0.2% higher over the last 30 days to the current level. Haemonetics' revenues are expected to be $303.28 million, down 9.8% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
